Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

DiaMedica Therapeutics Inc DMAC

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate DM199 (rinvecalinase alfa) is the first pharmaceutically active recombinant (synthetic) form of the human tissue kallikrein-1 (KLK1) protein to be clinically studied in patients. KLK1 is an established therapeutic modality in Asia, with human urinary KLK1, for the treatment of acute ischemic stroke and cardio renal disease, including hypertension. It has also produced a potential novel treatment for severe inflammatory diseases, DM300, which is in the early preclinical stage of development. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. KLK1 plays a critical role in the regulation of local blood flow and vasodilation in the body, as well as an important role in reducing inflammation and oxidative stress.


NDAQ:DMAC - Post by User

Bullboard Posts
Comment by joelouon Oct 14, 2018 2:04am
66 Views
Post# 28796474

RE:RE:US LISTING

RE:RE:US LISTINGHmmm. That’s the 64 thousand dollar question... now that 157 million share count doesn’t include outstanding warrants I do believe.. its a bit higher... nonetheless, I think they’ll want to get the shareprice quite a bit higher than the $2 US threshold to give them some wiggle room. My guess is anywhere between 3.50-4 US.  So I think we are going to see a consolidation somewhere in the range of 1 share for every 8 to 10 ... it really depends on the shareprice when the deal happens... hopefully higher since that will reduce the amount they have to consolidate...  I’m sure they have been consulting with their largest shareholders to get their input... and also, we’ll have to vote on it. 
I understand the need to get on the US board but I hope they couple this with some more positive news.. stock consolidations can be tricky if not handled right.  Just take a look at ONC on TSX to see how they are doing after their transaction — not much fun going on there!  
JL
Bullboard Posts